SCHEMBL1815476

SCHEMBL1815476

[c]1ccc(N2CCN(C3CCC3)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 5/20 0.58
L3MBTL1 Q9Y468 5/20 0.58
MBTD1 Q05BQ5 3/20 0.53
GRIN2B Q13224 1/20 0.49
HRH3 Q9Y5N1 5/20 0.48
TP53BP1 Q12888 2/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL4 Q8NA19 1/20 0.43
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3963086 0.95 L3MBTL3 (0.56) L3MBTL3L3MBTL1MBTD1GRIN2BHRH3
SCHEMBL1811223 0.92 L3MBTL3 (0.57) L3MBTL3L3MBTL1MBTD1GRIN2BKMT2A
SCHEMBL27896079 0.87 L3MBTL3 (0.78) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4041212 0.85 L3MBTL3 (0.75) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL27879361 0.84 L3MBTL3 (0.53) L3MBTL3L3MBTL1MBTD1GRIN2BTP53BP1
SCHEMBL16570211 0.84 HRH3 (0.49) L3MBTL3L3MBTL1MBTD1HRH3
SCHEMBL281977 0.82 L3MBTL3 (0.55) L3MBTL3L3MBTL1MBTD1GRIN2BTP53BP1
SCHEMBL13648728 0.81 L3MBTL3 (0.72) L3MBTL3L3MBTL1MBTD1GRIN2BHRH3
SCHEMBL20522873 0.80 L3MBTL3 (0.43) L3MBTL3L3MBTL1MBTD1GRIN2BKMT2A
SCHEMBL4612961 0.80 L3MBTL3 (0.56) L3MBTL3L3MBTL1MBTD1GRIN2BHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2017278-B1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE MSD KK (JP) 2016-11-02 EP disclosed
EP-2376493-B1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE MSD KK (JP) 2016-10-05 EP disclosed
US-20140303178-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES MSD KK (JP) 2014-10-09 US disclosed
US-8791125-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2014-07-29 US disclosed
US-8575179-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2013-11-05 US disclosed
US-8507505-B2 Dihydropyrazolopyrimidinone derivative MSD K.K. (JP) 2013-08-13 US disclosed
EP-2376494-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES MSD K.K. (JP) 2011-10-19 EP disclosed
EP-2376493-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE MSD K.K. (JP) 2011-10-19 EP disclosed
US-20110245229-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES MSD K.K. (JP) 2011-10-06 US disclosed
US-20110243891-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE MSD K.K. 2011-10-06 US disclosed
US-20110189130-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES SAGARA TAKESHI 2011-08-04 US disclosed
US-7935708-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2011-05-03 US disclosed
US-7834019-B2 Substituted pyrazolo[3,4-d]pyrimidinone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US disclosed
WO-2010067886-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-06-17 WO disclosed
WO-2010067888-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-06-17 WO disclosed
US-20100063024-A1 Dihydropyrazolopyrimidinone Derivatives MERCK SHARP & DOHME LLC 2010-03-11 US disclosed
CN-101432284-A Dihydropyrazolopyrimidinone derivative BANYU PHARMA CO LTD (JP) 2009-05-13 CN disclosed
EP-2017278-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-01-21 EP disclosed
US-20070254892-A1 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245229-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES WEE2, WEE1, CDKL1 L3MBTL3 2681/4885L3MBTL1 2445/4885MBTD1 4059/4885
US-20110189130-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES WEE1, WEE2, GRK3 L3MBTL3 1680/4885L3MBTL1 1501/4885MBTD1 3180/4885
US-20100063024-A1 Dihydropyrazolopyrimidinone Derivatives WEE1, WEE2, GRK3 L3MBTL3 1680/4885L3MBTL1 1501/4885MBTD1 3180/4885
US-20070254892-A1 Dihydropyrazolopyrimidinone derivatives WEE1, WEE2, GRK3 L3MBTL3 1680/4885L3MBTL1 1501/4885MBTD1 3180/4885
US-20110243891-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE WEE2, WEE1, RPS6KA1 L3MBTL3 3314/4885L3MBTL1 3108/4885MBTD1 3616/4885
US-20140303178-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES WEE1, WEE2, GRK3 L3MBTL3 1680/4885L3MBTL1 1501/4885MBTD1 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.